These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 7927731)

  • 21. The Lyme disease vaccine candidate outer surface protein A (OspA) in a formulation compatible with human use protects mice against natural tick transmission of B. burgdorferi.
    Golde WT; Burkot TR; Piesman J; Dolan MC; Capiau C; Hauser P; Dequesne G; Lobet Y
    Vaccine; 1995 Apr; 13(5):435-41. PubMed ID: 7639011
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Protective immunity elicited by recombinant bacille Calmette-Guerin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine.
    Stover CK; Bansal GP; Hanson MS; Burlein JE; Palaszynski SR; Young JF; Koenig S; Young DB; Sadziene A; Barbour AG
    J Exp Med; 1993 Jul; 178(1):197-209. PubMed ID: 8315378
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Plasmid DNA and protein vaccination of mice to the outer surface protein A of Borrelia burgdorferi leads to induction of T helper cells with specificity for a major epitope and augmentation of protective IgG antibodies in vivo.
    Zhong W; Wiesmüller KH; Kramer MD; Wallich R; Simon MM
    Eur J Immunol; 1996 Nov; 26(11):2749-57. PubMed ID: 8921965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Modulation of lymphocyte proliferative responses by a canine Lyme disease vaccine of recombinant outer surface protein A (OspA).
    Chiao JW; Villalon P; Schwartz I; Wormser GP
    FEMS Immunol Med Microbiol; 2000 Jul; 28(3):193-6. PubMed ID: 10865170
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Borrelia burgdorferi antigens that are targeted by antibody-dependent, complement-mediated killing in the rhesus monkey.
    Aydintug MK; Gu Y; Philipp MT
    Infect Immun; 1994 Nov; 62(11):4929-37. PubMed ID: 7927774
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tripalmitoyl-S-glyceryl-cysteine-dependent OspA vaccination of toll-like receptor 2-deficient mice results in effective protection from Borrelia burgdorferi challenge.
    Yoder A; Wang X; Ma Y; Philipp MT; Heilbrun M; Weis JH; Kirschning CJ; Wooten RM; Weis JJ
    Infect Immun; 2003 Jul; 71(7):3894-900. PubMed ID: 12819074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Production of borreliacidal antibody to outer surface protein A in vitro and modulation by interleukin-4.
    Munson EL; Du Chateau BK; Jobe DA; Lovrich SD; Callister SM; Schell RF
    Infect Immun; 2000 Oct; 68(10):5496-501. PubMed ID: 10992445
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Incomplete protection of hamsters vaccinated with unlipidated OspA from Borrelia burgdorferi infection is associated with low levels of antibody to an epitope defined by mAb LA-2.
    Johnson BJ; Sviat SL; Happ CM; Dunn JJ; Frantz JC; Mayer LW; Piesman J
    Vaccine; 1995 Aug; 13(12):1086-94. PubMed ID: 7491816
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Activation of monocytes by three OspA vaccine candidates: lipoprotein OspA is a potent stimulator of monokines.
    Häupl T; Landgraf S; Netusil P; Biller N; Capiau C; Desmons P; Hauser P; Burmester GR
    FEMS Immunol Med Microbiol; 1997 Sep; 19(1):15-23. PubMed ID: 9322065
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Circumvention of outer surface protein A immunity by host-adapted Borrelia burgdorferi.
    Barthold SW; Fikrig E; Bockenstedt LK; Persing DH
    Infect Immun; 1995 Jun; 63(6):2255-61. PubMed ID: 7768606
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phenotypic analysis of outer surface protein C (OspC) of Borrelia burgdorferi sensu lato by monoclonal antibodies: relationship to genospecies and OspA serotype.
    Wilske B; Jauris-Heipke S; Lobentanzer R; Pradel I; Preac-Mursic V; Rössler D; Soutschek E; Johnson RC
    J Clin Microbiol; 1995 Jan; 33(1):103-9. PubMed ID: 7699024
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Characterization of recombinant OspA in two different Borrelia vaccines with respect to immunological response and its relationship to functional parameters.
    Grosenbaugh DA; De Luca K; Durand PY; Feilmeier B; DeWitt K; Sigoillot-Claude C; Sajous ML; Day MJ; David F
    BMC Vet Res; 2018 Oct; 14(1):312. PubMed ID: 30326885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral vaccination with an attenuated Salmonella typhimurium strain expressing Borrelia burgdorferi OspA prevents murine Lyme borreliosis.
    Dunne M; al-Ramadi BK; Barthold SW; Flavell RA; Fikrig E
    Infect Immun; 1995 Apr; 63(4):1611-4. PubMed ID: 7890431
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of protection in rabbits against host-adapted and cultivated Borrelia burgdorferi following infection-derived immunity or immunization with outer membrane vesicles or outer surface protein A.
    Shang ES; Champion CI; Wu XY; Skare JT; Blanco DR; Miller JN; Lovett MA
    Infect Immun; 2000 Jul; 68(7):4189-99. PubMed ID: 10858236
    [TBL] [Abstract][Full Text] [Related]  

  • 35. DbpA, but not OspA, is expressed by Borrelia burgdorferi during spirochetemia and is a target for protective antibodies.
    Cassatt DR; Patel NK; Ulbrandt ND; Hanson MS
    Infect Immun; 1998 Nov; 66(11):5379-87. PubMed ID: 9784547
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Lyme borreliosis in transgenic mice tolerant to OspA from Borrelia burgdorferi 25015.
    Fikrig E; Barthold SW; Chen M; Tao H; Ali-Salaam P; Bockenstedt LK; Flavell RA
    J Infect Dis; 1997 Apr; 175(4):1000-3. PubMed ID: 9086169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new approach to a Lyme disease vaccine.
    Livey I; O'Rourke M; Traweger A; Savidis-Dacho H; Crowe BA; Barrett PN; Yang X; Dunn JJ; Luft BJ
    Clin Infect Dis; 2011 Feb; 52 Suppl 3():s266-70. PubMed ID: 21217174
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Reactivity with a specific epitope of outer surface protein A predicts protection from infection with the Lyme disease spirochete, Borrelia burgdorferi.
    Golde WT; Piesman J; Dolan MC; Kramer M; Hauser P; Lobet Y; Capiau C; Desmons P; Voet P; Dearwester D; Frantz JC
    Infect Immun; 1997 Mar; 65(3):882-9. PubMed ID: 9038292
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Borrelia burgdorferi stimulates the production of interleukin-10 in peripheral blood mononuclear cells from uninfected humans and rhesus monkeys.
    Giambartolomei GH; Dennis VA; Philipp MT
    Infect Immun; 1998 Jun; 66(6):2691-7. PubMed ID: 9596735
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Bone marrow-derived macrophage lines and immortalized cloned macrophage and dendritic cells support priming of Borrelia burgdorferi--specific T cell responses in vitro and/or in vivo.
    Altenschmidt U; Ricciardi-Castagnoli P; Modolell M; Otto H; Wiesmüller KH; Jung G; Simon MM
    Immunol Lett; 1996 Apr; 50(1-2):41-9. PubMed ID: 8793558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.